|
DE19531277A1
(de)
*
|
1995-08-25 |
1997-02-27 |
Basf Ag |
Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
|
|
DE19536387A1
(de)
*
|
1995-09-29 |
1997-04-03 |
Basf Ag |
Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
|
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
TW568788B
(en)
*
|
1998-10-12 |
2004-01-01 |
Chugai Pharmaceutical Co Ltd |
Polymer combining with phosphoric acid and preparation containing the same
|
|
JP3572213B2
(ja)
*
|
1999-01-18 |
2004-09-29 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース
|
|
US6733789B1
(en)
|
1999-01-21 |
2004-05-11 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
|
JP2000327701A
(ja)
*
|
1999-05-18 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
低置換度ヒドロキシプロピルセルロース及び固形製剤
|
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
|
DE19934610A1
(de)
*
|
1999-07-23 |
2001-01-25 |
Bayer Ag |
Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
|
|
EP1206633B1
(de)
|
1999-08-24 |
2004-10-20 |
Siemens Aktiengesellschaft |
Ansaugeinrichtung für eine brennkraftmaschine
|
|
KR100785360B1
(ko)
*
|
1999-09-24 |
2007-12-18 |
얀센 파마슈티카 엔.브이. |
항바이러스 조성물
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
DE60028754T2
(de)
*
|
1999-11-12 |
2007-05-31 |
Abbott Laboratories, Abbott Park |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
US7842308B2
(en)
*
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
US7883721B2
(en)
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
US20050175687A1
(en)
*
|
2001-01-30 |
2005-08-11 |
Mcallister Stephen M. |
Pharmaceutical formulations
|
|
GB0102342D0
(en)
*
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
KR20040100835A
(ko)
*
|
2001-02-15 |
2004-12-02 |
킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 |
안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
|
|
CA2450957A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030175337A1
(en)
*
|
2001-10-29 |
2003-09-18 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
|
US20030118652A1
(en)
*
|
2001-11-15 |
2003-06-26 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
US20030091633A1
(en)
*
|
2001-11-15 |
2003-05-15 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
IL162870A0
(en)
|
2002-02-01 |
2005-11-20 |
Pfizer Prod Inc |
Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
|
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
KR20040011248A
(ko)
*
|
2002-07-30 |
2004-02-05 |
환인제약 주식회사 |
암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
|
|
AU2003249474A1
(en)
|
2002-08-12 |
2004-02-25 |
Pfizer Products Inc. |
Pharmaceutical compositions of semi-ordered drugs and polymers
|
|
WO2004037237A1
(en)
|
2002-10-24 |
2004-05-06 |
Immupharm A/S |
Pharmaceutical compositions comprising flavonoids and menthol
|
|
EP1578415B1
(en)
|
2002-12-20 |
2008-09-10 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
|
WO2004069180A2
(en)
*
|
2003-01-31 |
2004-08-19 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
|
TW200526274A
(en)
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
KR20060096076A
(ko)
*
|
2003-11-14 |
2006-09-05 |
화이자 프로덕츠 인크. |
비만 치료를 위한 ｍｔｐ 저해제의 고형 무정형 분산물
|
|
CA2547404A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Pfizer Inc. |
Compositions comprising an hiv protease inhibitor
|
|
CA2555133A1
(en)
|
2004-02-04 |
2005-09-01 |
Pfizer Products Inc. |
Substituted quinoline compounds
|
|
AR048033A1
(es)
|
2004-03-12 |
2006-03-22 |
Smithkline Beecham Plc |
Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
|
|
BRPI0510273A
(pt)
|
2004-05-25 |
2007-10-30 |
Pfizer Prod Inc |
derivados de tetraazabenzo[e]azuleno e análogos destes
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
CN102631325A
(zh)
*
|
2004-08-12 |
2012-08-15 |
利洁时保健（英国）有限公司 |
通过熔体挤出制备的包含非类固醇类抗炎药和糖醇的颗粒剂
|
|
EP1941798B1
(en)
|
2004-12-17 |
2012-05-23 |
Devgen NV |
Nematicidal compositions
|
|
WO2006082518A1
(en)
|
2005-02-03 |
2006-08-10 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
EP1881819A1
(en)
*
|
2005-05-10 |
2008-01-30 |
Novartis AG |
Extrusion process for making compositions with poorly compressible therapeutic compounds
|
|
ES2628883T3
(es)
*
|
2006-03-24 |
2017-08-04 |
Auxilium International Holdings, Inc. |
Procedimiento para la preparación de un laminado extruido en estado fundido en caliente
|
|
AU2007230730B2
(en)
|
2006-03-24 |
2013-03-28 |
Auxilium International Holdings, Inc. |
Stabilized compositions containing alkaline labile drugs
|
|
US20090258953A1
(en)
*
|
2006-06-07 |
2009-10-15 |
Basf Se |
Use of vinyl acetate-sulfonate copolymers as solubilizers for slightly water-solubable compounds
|
|
US8343547B2
(en)
*
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
US20100179198A1
(en)
*
|
2007-07-06 |
2010-07-15 |
Murat Mertoglu |
Use of homo- and copolymers for stabilizing active ingredient formulations
|
|
KR20100033419A
(ko)
*
|
2007-07-19 |
2010-03-29 |
메타볼렉스, 인코포레이티드 |
당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
|
|
EP2219624A2
(en)
|
2007-11-08 |
2010-08-25 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
|
AU2009207796B2
(en)
|
2008-01-25 |
2014-03-27 |
Grunenthal Gmbh |
Pharmaceutical dosage form
|
|
BRPI0909469A2
(pt)
*
|
2008-03-31 |
2015-12-29 |
Metabolex Inc |
compostos de oximetileno de arila e usos dos mesmos
|
|
HRP20161307T1
(hr)
|
2008-05-09 |
2016-12-02 |
Grünenthal GmbH |
Postupak za pripravu praškaste formulacije međuproizvoda i konačni kruti oblik doziranja uz korištenje koraka zgrušavanja raspršivanjem
|
|
CA2727630A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
KR20110031485A
(ko)
*
|
2008-07-03 |
2011-03-28 |
노파르티스 아게 |
용융 과립화 방법
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
PE20120631A1
(es)
|
2009-07-22 |
2012-06-06 |
Gruenenthal Chemie |
Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
|
|
CA2765971C
(en)
|
2009-07-22 |
2017-08-22 |
Gruenenthal Gmbh |
Hot-melt extruded controlled release dosage form
|
|
US8410127B2
(en)
|
2009-10-01 |
2013-04-02 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
|
ES2676209T3
(es)
|
2010-06-23 |
2018-07-17 |
Metabolex Inc. |
Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
AR082862A1
(es)
|
2010-09-02 |
2013-01-16 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico
|
|
PL2611426T3
(pl)
|
2010-09-02 |
2014-09-30 |
Gruenenthal Gmbh |
Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
|
|
MX341873B
(es)
|
2010-12-23 |
2016-09-06 |
Abbvie Deutschland |
Formulaciones solidas de retardo basadas en dispersiones solidas.
|
|
WO2012110469A1
(en)
|
2011-02-17 |
2012-08-23 |
F. Hoffmann-La Roche Ag |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
MX358650B
(es)
|
2011-03-21 |
2018-08-30 |
Boehringer Ingelheim Int |
Preparacion solida con contenido de ambroxol.
|
|
HRP20171458T1
(hr)
|
2011-07-29 |
2017-11-17 |
Grünenthal GmbH |
Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
|
|
KR20140053159A
(ko)
|
2011-07-29 |
2014-05-07 |
그뤼넨탈 게엠베하 |
즉시 약물 방출을 제공하는 탬퍼-저항성 정제
|
|
JP6117249B2
(ja)
|
2012-02-28 |
2017-04-19 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
|
|
AP2014007953A0
(en)
|
2012-04-06 |
2014-09-30 |
Pfizer |
Diacylglycerol acyltransferase 2 inhibitors
|
|
PT2838512T
(pt)
|
2012-04-18 |
2018-11-09 |
Gruenenthal Gmbh |
Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
WO2014083067A1
(en)
*
|
2012-11-27 |
2014-06-05 |
Dsm Ip Assets B. V. |
Process for the production of discrete solid extruded particles
|
|
BR112015026549A2
(pt)
|
2013-05-29 |
2017-07-25 |
Gruenenthal Gmbh |
forma de dosagem à prova de violação contendo uma ou mais partículas
|
|
US9737490B2
(en)
|
2013-05-29 |
2017-08-22 |
Grünenthal GmbH |
Tamper resistant dosage form with bimodal release profile
|
|
US10646573B2
(en)
*
|
2013-06-03 |
2020-05-12 |
Shin-Etsu Chemical Co., Ltd. |
Composition for hot melt extrusion and method for producing hot melt extrudate by using same
|
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
|
BR112016010942B1
(pt)
*
|
2013-11-15 |
2020-11-24 |
Dsm Ip Assets B.V |
Formulaqao de compostos pouco soluveis por meio de extrusao por fusao a quente e processo de extrusao por fusao a quente para a produqao da mesma
|
|
HK1224189A1
(zh)
|
2013-11-26 |
2017-08-18 |
Grünenthal GmbH |
通过低温研磨制备粉状药物组合物
|
|
SI3119757T1
(en)
|
2014-03-17 |
2018-08-31 |
Pfizer Inc. |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
|
EP3142646A1
(en)
|
2014-05-12 |
2017-03-22 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
WO2015181059A1
(en)
|
2014-05-26 |
2015-12-03 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
|
HK1246173A1
(zh)
|
2015-04-24 |
2018-09-07 |
Grünenthal GmbH |
具有立即释放和对溶剂萃取的抗性的抗篡改剂型
|
|
WO2017042325A1
(en)
|
2015-09-10 |
2017-03-16 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
BR112018006720B1
(pt)
|
2015-10-07 |
2023-05-02 |
Dsm Ip Assets B.V |
Extrusados multivitamínicos, alimento, ração, formulações para cuidado pessoal e/ou farmacológicas ou pré-misturas dos mesmos
|
|
US10292983B2
(en)
|
2016-08-03 |
2019-05-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
EP3558272A1
(en)
|
2016-12-23 |
2019-10-30 |
Hermes Arzneimittel GmbH |
Oral pharmaceutical composition with improved taste-masking properties
|
|
WO2018163066A1
(en)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
|
US11254660B2
(en)
|
2018-08-31 |
2022-02-22 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
|
US11203594B2
(en)
|
2019-04-19 |
2021-12-21 |
Pfizer Inc. |
Anti-proliferative agents for treating PAH
|
|
EP3972596B1
(en)
|
2019-05-20 |
2025-07-16 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
WO2020261144A1
(en)
|
2019-06-28 |
2020-12-30 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶２ 抑制劑
|
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
|
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
|
|
FI4161927T3
(fi)
|
2020-06-09 |
2024-10-03 |
Pfizer |
Spiroyhdisteitä melanokortiini-4-reseptorin antagonisteina ja niiden käyttöjä
|
|
JP7704982B2
(ja)
|
2021-12-01 |
2025-07-08 |
ファイザー・インク |
糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
|
|
ES3039638T3
(en)
|
2021-12-06 |
2025-10-23 |
Pfizer |
Melanocortin 4 receptor antagonists and uses thereof
|
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
|
EP4605076A1
(en)
|
2022-10-18 |
2025-08-27 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
|
EP4604955A1
(en)
|
2022-10-18 |
2025-08-27 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
CN120731201A
(zh)
|
2022-12-16 |
2025-09-30 |
辉瑞公司 |
含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
|